Share This Page
PIPERACILLIN Drug Patent Profile
✉ Email this page to a colleague
When do Piperacillin patents expire, and what generic alternatives are available?
Piperacillin is a drug marketed by Istituto Bio Ita Spa, Apotex, Astral, Eugia Pharma, Eugia Pharma Speclts, Fresenius Kabi, Fresenius Kabi Usa, Hospira Inc, Milla Pharms, Onesource Specialty, Sagent Pharms Inc, Sandoz, Shandong, and B Braun Medical. and is included in twenty-five NDAs.
The generic ingredient in PIPERACILLIN is piperacillin sodium; tazobactam sodium. There are two drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the piperacillin sodium; tazobactam sodium profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for PIPERACILLIN?
- What are the global sales for PIPERACILLIN?
- What is Average Wholesale Price for PIPERACILLIN?
Summary for PIPERACILLIN
| US Patents: | 0 |
| Applicants: | 14 |
| NDAs: | 25 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Clinical Trials: | 112 |
| Patent Applications: | 6,955 |
| Drug Prices: | Drug price information for PIPERACILLIN |
| DailyMed Link: | PIPERACILLIN at DailyMed |
Recent Clinical Trials for PIPERACILLIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| The Swedish Research Council | PHASE4 |
| Uppsala University | PHASE4 |
| Uppsala Clinical Research Center, Sweden | PHASE4 |
US Patents and Regulatory Information for PIPERACILLIN
Piperacillin Market Dynamics and Financial Trajectory
Piperacillin is a mature, off-patent beta-lactam antibiotic whose commercial value is concentrated in the injectable combination piperacillin/tazobactam, formerly marketed in the United States as Zosyn. The market is driven by hospital demand, generic contract supply, injectable manufacturing capacity, antimicrobial-resistance patterns, and periodic shortages rather than by patent pricing power. Originator economics have largely disappeared, while manufacturers with reliable sterile production, regulatory-compliant facilities, and global distribution retain commercial value.
What is the current market position of piperacillin?
Piperacillin is an extended-spectrum ureidopenicillin used primarily with tazobactam, a beta-lactamase inhibitor. The combination is administered intravenously for serious bacterial infections, including hospital-acquired pneumonia, intra-abdominal infections, skin and soft-tissue infections, urinary tract infections, and bloodstream infections.
In practice, piperacillin/tazobactam is the relevant commercial product. Piperacillin monotherapy has limited market importance because tazobactam expands activity against beta-lactamase-producing organisms.
| Market characteristic | Piperacillin/tazobactam position |
|---|---|
| Primary dosage form | Sterile intravenous injection or infusion |
| Main customers | Hospitals, health systems, government purchasers, wholesalers |
| Regulatory status | Established generic injectable |
| Originator brand | Zosyn, developed and commercialized by Wyeth, later Pfizer |
| Patent position | Core product protection expired |
| Pricing power | Low |
| Main competitive factors | Supply reliability, price, quality, contract access, shortage performance |
| Principal substitutes | Cefepime, meropenem, ceftriaxone, ceftazidime, ampicillin/sulbactam |
| Key clinical constraint | Resistance, renal dosing, allergy risk, and antimicrobial-stewardship controls |
The product is included in the World Health Organization’s Model List of Essential Medicines in the piperacillin/tazobactam category, supporting continued use in hospital systems globally (World Health Organization, 2023).
How large is the piperacillin market?
A precise global revenue figure for piperacillin is not publicly reported on a consistent basis. Pharmaceutical companies generally aggregate sales under hospital anti-infectives, sterile injectables, or generic antibiotics. Market-research estimates vary materially because some include piperacillin/tazobactam only, while others combine all hospital penicillins or injectable broad-spectrum antibiotics.
The economically relevant market is therefore best analyzed through product volume, hospital procurement, and supplier concentration rather than branded pharmaceutical revenue.
Market segmentation
Piperacillin/tazobactam demand is segmented by:
- Hospital inpatient use
- Intensive-care and emergency medicine
- Surgical and intra-abdominal infection treatment
- Pneumonia and bloodstream infection management
- Government and public-hospital procurement
- Premixed infusion bags
- Pharmacy-compounded vials
- Regional generic tenders
- Outpatient parenteral antimicrobial therapy
The United States, Europe, Japan, China, India, and large public-health systems in Latin America and the Middle East represent the principal demand centers. Volume growth is strongest in markets where hospital capacity, bacterial resistance, and access to injectable antibiotics are expanding. Revenue growth is weaker because most sales occur through generic tenders.
When did piperacillin lose exclusivity?
Piperacillin’s core composition-of-matter exclusivity expired decades ago. The product is not protected by an active U.S. innovator patent estate capable of supporting branded pricing.
Zosyn received U.S. approval in combination with tazobactam in the early 1990s. Pfizer’s product later faced generic competition after expiration of relevant patents and regulatory exclusivity. The U.S. Food and Drug Administration approved generic versions of piperacillin and tazobactam for injection from multiple manufacturers, including major generic injectable suppliers.
| Exclusivity category | Current position |
|---|---|
| Core active ingredient patent | Expired |
| Piperacillin/tazobactam combination protection | Expired |
| Brand exclusivity | Expired |
| Orphan-drug exclusivity | Not applicable |
| Pediatric exclusivity | Not a current commercial barrier |
| FDA generic pathway | Abbreviated New Drug Application |
| Biosimilar pathway | Not applicable |
The remaining intellectual-property value is generally limited to manufacturing processes, packaging, device combinations, stability data, and formulation improvements. Those rights do not recreate the market position once held by Zosyn.
What is the Orange Book status of piperacillin/tazobactam?
Piperacillin/tazobactam is an FDA-approved small-molecule generic injectable product. Orange Book relevance is limited to listed patents and therapeutic-equivalence determinations associated with approved reference products.
The product is not a biologic and does not rely on the Biologics Price Competition and Innovation Act pathway. Generic applicants typically file ANDAs referencing an FDA-listed reference product and demonstrate pharmaceutical equivalence, bioequivalence where applicable, and compliance with injectable-product quality standards.
The commercial issues are usually manufacturing capacity and approval status rather than patent clearance.
Paragraph IV challenges
Paragraph IV litigation has historically been relevant to generic versions of branded drugs with active Orange Book patents. For piperacillin/tazobactam, that mechanism has limited present-day importance because the principal patent barriers have expired.
Generic entrants can still face:
- FDA complete-response letters
- Facility inspections
- Sterility failures
- Chemistry, manufacturing, and controls deficiencies
- Labeling disputes
- Supply-chain qualification delays
- Contracting barriers with hospitals and group purchasing organizations
A new applicant’s principal launch risk is usually regulatory and operational, not patent litigation.
What patents protect piperacillin products today?
The active ingredient and core combination are not protected by commercially meaningful composition patents in the United States. Potentially relevant rights may exist around:
- Stabilized piperacillin/tazobactam compositions
- Ready-to-use infusion bags
- Reconstitution systems
- Freeze-drying or lyophilization
- Container-closure systems
- Manufacturing and purification methods
- Extended-storage formulations
- Combination products with infusion devices
These rights are generally narrow and jurisdiction-specific. They may affect a particular presentation but do not block standard vial-based generic entry.
| Patent category | Commercial relevance |
|---|---|
| Composition of matter | Low; expired |
| Combination patent | Low; expired |
| Injectable formulation | Product-specific |
| Premixed infusion system | Potentially relevant |
| Manufacturing process | Potentially relevant but difficult to enforce broadly |
| Packaging and device | Relevant to presentation-specific products |
| Method of use | Limited because indications are established and label overlap is broad |
A complete patent freedom-to-operate analysis requires review of country-specific registers, patent-family status, terminal disclaimers, prosecution history, and litigation records. The broad market conclusion is clear: piperacillin/tazobactam is an off-patent generic injectable market.
What formulations are protected by piperacillin-related patents?
The commercially important presentations are sterile powders for reconstitution and premixed intravenous solutions. Premixed bags can command a higher price than standard vials because they reduce pharmacy preparation time and handling requirements.
Standard vial formulations
Vial products have the broadest generic competition. Their economics depend on:
- Active pharmaceutical ingredient cost
- Sterile filling capacity
- Quality-control costs
- Hospital contract pricing
- Batch size
- Fill-finish utilization
- Regulatory compliance
Premixed infusion formulations
Premixed products can retain stronger margins because they provide operational benefits. They may use proprietary containers, stability profiles, or storage conditions. Products marketed in flexible bags can face device, packaging, and manufacturing patents even when the active drug is unprotected.
The practical barrier is often capital expenditure and validated sterile production rather than patent exclusion.
Extended-stability products
Products with longer refrigerated or room-temperature stability can reduce hospital waste and simplify inventory management. Stability improvements may support differentiated contracting, but they generally produce limited pricing power in tenders unless the product solves a recognized shortage or workflow problem.
Which companies compete in the piperacillin market?
The competitive landscape includes originator-linked suppliers, multinational generic manufacturers, regional injectable specialists, and contract manufacturers.
Relevant manufacturers and suppliers have included:
- Pfizer, through the historical Zosyn brand and associated sterile anti-infective operations
- Sandoz
- Fresenius Kabi
- Hikma Pharmaceuticals
- Aurobindo Pharma
- Eugia Pharma
- Apotex
- DailyMed-listed regional generic suppliers
- Contract sterile-injectable manufacturers serving hospital tenders
Availability differs by country and over time. A company may hold FDA approval without maintaining continuous commercial supply. Hospital purchasing decisions often depend on a manufacturer’s shortage record, allocation policy, approved alternative presentations, and wholesaler inventory.
Competitive comparison
| Factor | Piperacillin/tazobactam | Cefepime | Meropenem |
|---|---|---|---|
| Patent maturity | Generic | Generic | Generic |
| Broad Gram-negative coverage | High | High | Very high |
| Anaerobic coverage | Strong with tazobactam | Limited | Strong |
| Carbapenem-sparing value | Yes | Yes | No |
| Stewardship pressure | Moderate | Moderate | High |
| Injectable manufacturing complexity | High | High | High |
| Price environment | Competitive | Competitive | Often higher |
| Shortage sensitivity | High | High | High |
Piperacillin/tazobactam remains clinically useful because it offers broad coverage without being a carbapenem. Hospitals may substitute cefepime plus metronidazole, meropenem, ceftazidime-based regimens, or other agents when supply or susceptibility data require it.
How do hospitals and stewardship programs affect demand?
Demand is shaped by clinical protocols rather than consumer marketing. Hospital antimicrobial-stewardship programs increasingly restrict broad-spectrum antibiotics and require culture-based de-escalation.
The main demand drivers are:
- Hospital admissions and intensive-care utilization.
- Growth in severe healthcare-associated infections.
- Local prevalence of susceptible organisms.
- Availability of competing beta-lactams.
- Antimicrobial-resistance surveillance.
- Surgical and abdominal infection volume.
- National procurement policies.
- Shortages of competing injectable antibiotics.
Stewardship can reduce duration of therapy and unnecessary use. That effect limits unit growth, but it does not eliminate demand because piperacillin/tazobactam remains a standard empiric option for severe polymicrobial and healthcare-associated infections.
Resistance creates a mixed commercial effect. Rising resistance can increase use of broader agents, but it can also reduce piperacillin/tazobactam’s place in therapy. Extended-spectrum beta-lactamase-producing organisms and difficult-to-treat Pseudomonas aeruginosa are particularly important clinical variables.
What regulatory factors affect piperacillin sales?
FDA regulation focuses on injectable-product quality, sterility, potency, impurities, container closure, and manufacturing controls. The principal regulatory pathway is the ANDA.
FDA approval does not guarantee commercial continuity. Sterile-injectable manufacturers face recurring risk from:
- Form 483 observations
- Warning letters
- Voluntary recalls
- Contamination events
- Component shortages
- API supply interruptions
- Delayed manufacturing transfers
- Inspection backlogs
- Batch-release failures
The FDA Drug Shortages database has repeatedly identified shortages involving injectable antibiotics and related hospital products. Availability problems can shift purchasing rapidly to alternative suppliers and create temporary price increases (U.S. Food and Drug Administration, 2024a).
What manufacturing and supply-chain barriers affect piperacillin?
Piperacillin/tazobactam is more difficult to manufacture than a typical oral generic. It requires sterile processing, validated aseptic operations, high-quality API, and tightly controlled packaging.
Key barriers include:
- Limited global sterile-fill capacity
- Dependence on Asian API suppliers
- Complex combination-product manufacturing
- Short shelf life for some presentations
- Cold-chain requirements for selected products
- Hospital inventory buffering
- Regulatory qualification of alternate sites
- High cost of facility remediation
- Low tender prices that discourage redundant capacity
The market can therefore experience shortages despite several approved suppliers. Generic competition lowers prices, while low prices can reduce investment in spare capacity. This creates a fragile supply structure in which a single plant outage can affect national availability.
How does piperacillin generate revenue for manufacturers?
Revenue is generated through high-volume, low-margin hospital sales. The principal commercial channels are:
- Direct hospital contracts
- Group purchasing organizations
- Wholesaler distribution
- Government tenders
- Public-health procurement
- Regional distributor networks
The financial profile differs by product presentation.
| Presentation | Volume | Margin potential | Main commercial advantage |
|---|---|---|---|
| Standard vial | High | Low | Broad hospital access |
| Bulk vial | Moderate | Low to moderate | Lower preparation cost |
| Premixed infusion bag | Moderate | Moderate | Pharmacy and nursing efficiency |
| Specialty stability presentation | Low | Moderate | Inventory and waste reduction |
| Branded product | Historically high | No longer dominant | Clinical familiarity |
The reference brand’s historical revenue declined after generic entry. Pfizer does not publicly report current piperacillin/tazobactam revenue as a standalone line item, and generic manufacturers generally do not disclose product-specific sales. The market’s financial trajectory is therefore a shift from branded monopoly economics to procurement-driven commodity economics.
What is the financial trajectory for piperacillin?
The long-term trajectory is stable to modestly declining in price, with volume supported by persistent hospital use.
Historical phase
During the branded period, Zosyn benefited from:
- Broad empiric coverage
- Hospital formulary adoption
- Strong physician familiarity
- Patent and regulatory barriers
- Higher branded pricing
Generic transition
After exclusivity loss, pricing declined as manufacturers entered the market. The originator’s share fell, while hospitals gained negotiating leverage. Generic supply became the principal source of volume.
Current phase
The current market has four financial characteristics:
- Low average selling prices for standard vials
- Higher price volatility during shortages
- Limited product differentiation
- Greater value for reliable sterile supply
Forward trajectory
Base-case market expectations are:
| Variable | Expected direction |
|---|---|
| Unit demand | Stable to modest growth |
| Branded revenue | Minimal |
| Generic price | Flat to declining outside shortages |
| Shortage-period pricing | Temporarily elevated |
| Manufacturing costs | Upward pressure |
| Premixed product value | More resilient than vial value |
| Patent-driven margin expansion | Unlikely |
| Regulatory compliance costs | Rising |
| Hospital procurement pressure | Persistent |
Revenue growth, where it occurs, is more likely to come from volume, geographic expansion, premixed formats, and supply reliability than from price increases.
What generic launch scenarios exist for piperacillin?
Scenario one: incumbent generic supply remains stable
Multiple approved suppliers maintain production. Prices remain compressed, and market share is allocated through tenders, contracts, and wholesaler relationships.
Scenario two: one major supplier exits
A plant closure, inspection failure, or commercial decision reduces supply. Remaining manufacturers gain temporary volume and pricing leverage. Hospitals may ration inventory or adopt cefepime, meropenem, or alternative combinations.
Scenario three: premixed products gain share
Hospitals favor products that reduce pharmacy labor and preparation risk. Manufacturers with validated bag technology can achieve better economics than suppliers selling standard vials alone.
Scenario four: resistance reduces utilization
Local resistance trends or updated stewardship protocols reduce empiric use. Demand shifts toward newer beta-lactam/beta-lactamase inhibitor products or carbapenem-sparing alternatives.
What patent litigation affects piperacillin?
Current litigation risk is limited relative to patented oncology, immunology, and specialty medicines. The most likely disputes concern:
- ANDA approval timing
- Product-labeling claims
- Device and container patents
- Manufacturing processes
- Trade secrets
- Contract manufacturing
- Quality failures and product liability
A conventional Paragraph IV launch battle is not the central risk for the mature piperacillin/tazobactam market. Litigation exposure is more likely to arise from a differentiated delivery system or a manufacturing dispute than from the active pharmaceutical ingredient.
Does piperacillin face biosimilar competition?
No. Piperacillin is a chemically synthesized small molecule, not a biologic. Biosimilar competition does not apply.
The relevant competitors are generic small-molecule injectables and other antibacterial drugs. FDA competition is governed by the ANDA framework, not the biosimilar pathway (U.S. Food and Drug Administration, 2024b).
What licensing deals affect piperacillin?
Piperacillin is not currently associated with a major growth-oriented licensing market. Historic commercialization involved originator licensing and corporate transactions surrounding Wyeth and Pfizer. Current licensing activity is more likely to involve:
- API supply agreements
- Contract sterile manufacturing
- Regional commercialization rights
- Government procurement arrangements
- Hospital distribution agreements
- Technology transfer for premixed bags or lyophilized products
The commercial value of a transaction depends primarily on manufacturing authorization, capacity access, regulatory history, and tender eligibility. A license to a standard piperacillin/tazobactam product without protected technology has limited strategic value.
How strong is the piperacillin patent estate?
The patent estate is weak for the core drug and combination, but it can be moderate for selected presentations.
| Estate component | Strength | Reason |
|---|---|---|
| Core molecule | Very low | Long-expired protection |
| Piperacillin/tazobactam combination | Very low | Mature generic product |
| Standard vial | Low | Multiple generic alternatives |
| Premixed bag | Moderate in limited jurisdictions | Packaging and stability differentiation |
| Manufacturing process | Low to moderate | Narrow scope and design-around potential |
| Method of use | Low | Established indications and clinical practice |
| Device combination | Moderate | Depends on claim scope and jurisdiction |
Patent strength should not be confused with commercial strength. A supplier can have strong market leverage through capacity and quality performance without holding enforceable exclusivity.
What geographic markets offer the strongest opportunity?
The largest opportunities are in countries with:
- High hospital utilization
- Growing critical-care infrastructure
- Public reimbursement
- Reliable injectable procurement
- Local manufacturing incentives
- Persistent shortages
- Rising antimicrobial resistance
The United States offers scale but has severe price competition and demanding FDA manufacturing standards. Europe has consolidated procurement and tender pressure. China and India have large hospital volumes and extensive domestic manufacturing, but pricing can be aggressive. Middle Eastern, Latin American, and Southeast Asian markets may offer opportunities through public tenders and regional distribution, subject to registration and local supply rules.
Geographic expansion is most attractive when a manufacturer has an approved product, local tender access, and dependable sterile capacity. Patent barriers generally do not determine entry.
Key Takeaways
- Piperacillin’s commercial market is principally piperacillin/tazobactam, not piperacillin monotherapy.
- The product is a mature generic injectable with expired core patent protection.
- Zosyn’s branded economics have been replaced by hospital procurement and supply-chain competition.
- Exact product-level revenue is not publicly disclosed by major manufacturers.
- Unit demand is likely to remain stable because piperacillin/tazobactam remains an important hospital empiric antibiotic.
- Price growth is limited outside periods of shortage.
- Sterile manufacturing capacity, FDA compliance, API security, and tender access are more important than patent ownership.
- Premixed infusion bags and stability-enhanced presentations offer the strongest potential for differentiation.
- Paragraph IV and biosimilar risks are limited; regulatory and manufacturing risks are more material.
- Revenue exposure is concentrated among generic injectable suppliers, contract manufacturers, wholesalers, and hospital procurement channels.
FAQs
Is piperacillin still under patent protection?
The core piperacillin and piperacillin/tazobactam protections have expired. Narrow patents may still affect specific formulations, packaging systems, or manufacturing processes in selected jurisdictions.
Is piperacillin/tazobactam a profitable generic?
It can be profitable when a supplier has efficient sterile manufacturing, reliable API access, and hospital contracts. Standard vial pricing is highly competitive, while premixed and shortage-constrained products can produce better margins.
What drug is most likely to replace piperacillin/tazobactam?
Cefepime plus metronidazole, meropenem, ceftazidime-based regimens, and newer beta-lactam/beta-lactamase inhibitor combinations are the main alternatives. The choice depends on infection site, susceptibility data, renal function, and stewardship policy.
Can a pharmaceutical company obtain market exclusivity for a new piperacillin formulation?
A company may obtain patent protection for a novel formulation, delivery system, stability profile, or manufacturing process. That protection would generally apply only to the claimed product or technology, not to standard piperacillin/tazobactam.
Why does piperacillin experience shortages despite having generic suppliers?
Sterile injectable production is concentrated, costly, and vulnerable to plant failures, API interruptions, quality events, and low tender prices. Several approved manufacturers do not necessarily mean that sufficient commercial capacity is available.
References
-
Pfizer Inc. (1992). Zosyn (piperacillin and tazobactam) prescribing information. U.S. Food and Drug Administration.
-
U.S. Food and Drug Administration. (2024a). Drug shortages. https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages
-
U.S. Food and Drug Administration. (2024b). Generic drug facts. https://www.fda.gov/drugs/generic-drugs/generic-drug-facts
-
U.S. Food and Drug Administration. (2024c). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
-
World Health Organization. (2023). WHO model list of essential medicines, 23rd list. https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.02
More… ↓
